293 related articles for article (PubMed ID: 32043797)
1. Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Hsu C; Marshall JL; He AR
Oncologist; 2020 Feb; 25(2):105-111. PubMed ID: 32043797
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
3. Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.
Singh BP; Marshall JL; He AR
Oncologist; 2020 Mar; 25(3):197-202. PubMed ID: 32162824
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
Kramer S; van Hee K; Blokzijl H; van der Heide F; Visschedijk MC
J Immunother; 2023 Sep; 46(7):271-275. PubMed ID: 37216403
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with IgG4-associated cholangitis.
Buechter M; Klein CG; Kloeters C; Schlaak JF; Canbay A; Gerken G; Kahraman A
Z Gastroenterol; 2014 Jun; 52(6):564-8. PubMed ID: 24905108
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature.
Tanabe K; Yokoyama K; Kanno A; Ikeda E; Ando K; Nagai H; Koyanagi T; Sakaguchi M; Nakaya T; Tamada K; Niki T; Fukushima N; Lefor AK; Yamamoto H
Intern Med; 2024 Mar; 63(6):791-798. PubMed ID: 37532549
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.
Reynolds K; Thomas M; Dougan M
Oncologist; 2018 Sep; 23(9):991-997. PubMed ID: 29853659
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis.
Shirwaikar Thomas A; Chari ST
Curr Gastroenterol Rep; 2023 Oct; 25(10):255-259. PubMed ID: 37845557
[TBL] [Abstract][Full Text] [Related]
9. Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis.
Li M; Wong D; Sack JS; Vogel AS; Hodi FS; Fong L; Lai JC; Grover S; Zucker SD
J Natl Compr Canc Netw; 2023 Jun; 21(6):617-626.e3. PubMed ID: 37308118
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
[TBL] [Abstract][Full Text] [Related]
11. Post-COVID-19 polyautoimmunity - Fact or coincidence: A case report.
Shorbagi AI; Obaideen A; Jundi M
Front Med (Lausanne); 2023; 10():1013125. PubMed ID: 37007767
[TBL] [Abstract][Full Text] [Related]
12. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
De Martin E; Michot JM; Rosmorduc O; Guettier C; Samuel D
JHEP Rep; 2020 Dec; 2(6):100170. PubMed ID: 33205034
[TBL] [Abstract][Full Text] [Related]
13. Immune-related pancreatitis associated with checkpoint blockade in melanoma.
Kohlmann J; Wagenknecht D; Simon JC; Ziemer M
Melanoma Res; 2019 Oct; 29(5):549-552. PubMed ID: 30964768
[TBL] [Abstract][Full Text] [Related]
14. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
15. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
16. Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study.
Fousekis FS; Katsanos KH; Theopistos VI; Baltayiannis G; Kosmidou M; Glantzounis G; Christou L; Tsianos EV; Christodoulou DK
BMC Gastroenterol; 2019 Apr; 19(1):48. PubMed ID: 30943899
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Pathological Features of Immune Checkpoint Inhibitor-induced Liver Injury in Comparison with Drug-induced Liver Injury and Autoimmune Hepatitis.
Sunago K; Abe M; Yoshida O; Watanabe T; Nakamura Y; Imai Y; Koizumi Y; Hirooka M; Tokumoto Y; Hiasa Y
J Gastrointestin Liver Dis; 2023 Dec; 32(4):488-496. PubMed ID: 38147620
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report.
Onishi S; Tajika M; Bando H; Matsubara Y; Hosoda W; Muro K; Niwa Y
J Med Case Rep; 2020 Nov; 14(1):230. PubMed ID: 33239098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
